Ariad Pharma Revenue, Profits - ARIA Quarterly Income Statement

Add to My Stocks
$23.99 $0 (0%) ARIA stock closing price Feb 16, 2017 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Ariad Pharma stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. Like any other income statement, the ARIA income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue decline of -32.45% when compared to the same period in the past. The operating expenses as shown in the Ariad Pharma profit and loss statement for 2016 Q3 total to $69.86M. This line item shows that the operating expenses has decreased compared with last year. Also check: Ariad Pharma assets and Ariad Pharma free cash flow.

View and download details of revenue and profits for Ariad Pharma for latest & last 40 quarters.
show more
Fiscal year is Jan - Dec2016 Q32016 Q22016 Q12015 Q4
Ariad Pharma Revenues or Net Sales
46.02M68.13M35.6M36.51M
Cost Of Goods Sold (COGS)1.13M1.1M--
Ariad Pharma Gross Profit
44.88M67.01M35.11M36.07M
Research & Development Expense43.62M42.86M44.07M44.83M
Selling General & Admin Expense26.24M35.81M38.89M43.84M
Income Before Depreciation Depletion Amortization-24.99M-11.66M-47.86M-52.6M
Depreciation Depletion Amortization----
Non Operating Income3.24M128.66M-0.72M-0.1M
Interest Expense8.42M5.4M4.94M5.26M
Ariad Pharma Pretax Income
-30.16M111.6M-53.53M-57.94M
Provision for Income Taxes-2.33M1.75M-1.94M
MinorityInterest----
Investment Gains Losses----
Other Income----
Income Before Extraordinaries & Disc Operations-27.83M109.85M-53.79M-59.87M
Extraordinary Items & Discontinued Operations----
Ariad Pharma Profit/ Loss (Net Income)
-27.83M109.85M-53.79M-59.87M
Average Shares used to compute Diluted EPS193.23M194.57M190.3M189.3M
Average Shares used to compute Basic EPS193.23M191.49M190.3M189.3M
Income Before Nonrecurring Items-27.83M111.42M-53.79M-59.87M
Income from Nonrecurring Items--1.57M--
Ariad Pharma Earnings Per Share Basic Net
-0.140.57-0.28-0.32
Ariad Pharma Earnings Per Share Diluted Net
-0.140.56-0.28-0.32
EPS Diluted Before Nonrecurring Items-0.140.57-0.28-0.32
Preferred Dividends Acc Pd----
Dividends Common----
Dividend Per Share Common0.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.

It is very helpful to read a report on Ariad Pharma stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Ariad Pharma revenue chart, implies that the company is growing. It has not been the case with Ariad Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like Ariad Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the ARIA income statement, one can check the Ariad Pharma historical stock prices to check how the price has moved with time.

Ariad Pharma Income Statement - Key Financial Ratios

Other Income Statements - Ariad Pharmaceuticals, Inc. Industry Peers

Amgen income statement, Bristol-Myers Squibb income statement, Fibrogen income statement